Hefei Lifeon Pharmaceutical (003020.SZ): Marketing application for dexmethylphenidate hydrochloride API approved
Lifeon Pharmaceutical (003020.SZ) announced that recently, the company received the "Approval Notice for Marketing Application of Chemical API" for dexmethylphenidate hydrochloride issued by the National Medical Products Administration. Dexmethylphenidate hydrochloride is a central nervous system stimulant used for the treatment of attention deficit hyperactivity disorder (ADHD).
Hefei Lifeon Pharmaceutical (003020.SZ) announced that recently, the company received the "Chemical API Marketing Application Approval Notification" for dexmethylphenidate hydrochloride issued by the National Medical Products Administration. Dexmethylphenidate hydrochloride is a central nervous system stimulant used for the treatment of attention deficit hyperactivity disorder (ADHD).
Related Articles
GUANGDONG INV (00270) will distribute an interim dividend of HK$0.2919 per share on October 28.
Jiangsu Hengrui Pharmaceuticals (600276.SH): HRS-1596 Tablets Receive Drug Clinical Trial Approval Notice
Jiangsu Hengrui Pharmaceuticals (600276.SH): SHR-4595 for Injection Receives Drug Clinical Trial Approval Notice
GUANGDONG INV (00270) will distribute an interim dividend of HK$0.2919 per share on October 28.
Jiangsu Hengrui Pharmaceuticals (600276.SH): HRS-1596 Tablets Receive Drug Clinical Trial Approval Notice
Jiangsu Hengrui Pharmaceuticals (600276.SH): SHR-4595 for Injection Receives Drug Clinical Trial Approval Notice
RECOMMEND
